Navigation Links
BELLUS Health inc. announces completion of first tranche of financing
Date:4/16/2009

LAVAL, QC, April 16 /PRNewswire-FirstCall/ - Further to the press releases of March 31 and April 8, 2009, BELLUS Health Inc. ("BELLUS Health") (TSX: BLU) is pleased to announce the completion of the first tranche of its previously announced Cdn. $20.5 million financing.

BELLUS Health received gross proceeds of Cdn. $10 million for the issuance of new convertible notes (Cdn.$5 million from Vitus Investments III Private Limited and Cdn.$5 million from Victoria Square Ventures Inc.) and a second tranche of Cdn.$10.5 (Cdn.$5 million from Vitus Investments III Private Limited and Cdn.$5.5 million from Victoria Square Ventures Inc.) is expected to be funded in June 2009.

About BELLUS Health

BELLUS Health is a global health company focused on the development and commercialization of products to provide innovative health solutions to address critical unmet needs.

To Contact BELLUS Health

For additional information on BELLUS Health and its drug development programs, please call the Canada and United States toll-free number 1-877-680-4500 or visit the Web Site at www.bellushealth.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond BELLUS Health Inc.'s control. Such risks include but are not limited to: the ability to obtain financing immediately in the current markets, the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the BELLUS Health Group does business, stock market volatility, the availability and terms of any financing, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, as well as other risks disclosed in public filings of BELLUS Health Inc. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and BELLUS Health Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see the Annual Information Form of BELLUS Health Inc. for further risk factors that might affect the BELLUS Health Group and its business.

CONTACT: Mariano Rodriguez, CA, CPA, Vice President, Finance, and Chief Financial Officer, (450) 680-4572, ir@bellushealth.com


'/>"/>
SOURCE BELLUS HEALTH INC.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BELLUS Health reports results for the fourth quarter of 2008
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BELLUS Health Inc.
3. BELLUS Health announces formal notice to voluntarily delist from NASDAQ
4. BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market
5. BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
6. BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update
7. BELLUS Health to present at the Rodman and Renshaw 10th Annual Healthcare Conference
8. BELLUS Health provides update on activities
9. BELLUS Health announces closing of Innodia acquisition
10. BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference
11. BELLUS HEALTH reports results for first quarter of fiscal 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2017)... ... January 14, 2017 , ... Wondering where to go ... delivered straight to your door for a romantic, lobster feast in the comfort of ... for Valentine's Day. The dinners will be featured until February 15th, 2017. , ...
(Date:1/15/2017)... NJ (PRWEB) , ... January 15, 2017 , ... ... firm located in Montclair, NJ is pleased to announce that it will be ... is located in Montclair and Glen Ridge townships, servicing all surrounding towns. The ...
(Date:1/14/2017)... ... January 13, 2017 , ... According to a ... Mediterranean diet may lower the risk of type 2 diabetes, Alzheimer’s, and cardiovascular ... health and wellness benefits linked to a Mediterranean diet are only some of ...
(Date:1/14/2017)... (PRWEB) , ... January 14, 2017 , ... "TransFreeze Volume 3 is a self animating ... mask effect in Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... a unique freeze frame transition from one clip to the next. , To ...
(Date:1/13/2017)... , ... January 13, 2017 , ... The 18th European ... America hotel on March 3-4, 2017. This Congress is expertly designed to meet ... management of patients with lung cancer. , Chaired by Dr. Giorgio V. Scagliotti, Professor ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... 16, 2017 The ... Type (Methyl, Ethyl, Hydroxyethyl, Hydroxypropyl, Carboxymethyl Cellulose), ... Surface Coatings & Paints), Region - Global ... market was valued at USD 4.51 Billion ... USD 6.41 Billion by 2021, at a ...
(Date:1/16/2017)... 2017  Dovetail Genomics today announced the commercial launch ... which yields chromosome-scale genome assemblies. The service is available ... on Jan. 17 at the Plant & Animal Genome ... . "We are thrilled to be expanding ... Dovetail Hi-C offering," said Todd Dickinson , Dovetail,s ...
(Date:1/15/2017)... January 16, 2017 Der Vorstand ... für die Regeneration des menschlichen Gewebes, gibt die Ernennung ... sofortiger Wirkung bekannt. ... Bill Allan ist ... bekleidete eine Reihe von Geschäftsführer- und anderen Führungspositionen bei ...
Breaking Medicine Technology: